{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T22:10:18Z","timestamp":1737324618925,"version":"3.33.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1097\/ico.0b013e318074e44d","type":"journal-article","created":{"date-parts":[[2007,7,24]],"date-time":"2007-07-24T08:03:13Z","timestamp":1185264193000},"page":"886-887","source":"Crossref","is-referenced-by-count":12,"title":["Sj\u00f6gren Keratoconjunctivitis Sicca Treated With Rituximab"],"prefix":"10.1097","volume":"26","author":[{"given":"Luis Fernando","family":"Zapata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz Marina","family":"Agudelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose David","family":"Paulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-25-20210204","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests.","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"R2-25-20210204","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0896-8411(89)90184-4","article-title":"Polyclonal B-cell activation is related to exocrine manifestations of primary Sjogrens syndrome.","volume":"2","author":"Oxholm","year":"1989","journal-title":"J Autoimmun"},{"key":"R3-25-20210204","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sjogrens syndrome.","volume":"109","author":"Groom","year":"2002","journal-title":"J Clin Invest"},{"key":"R4-25-20210204","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1191\/0961203302lu309oa","article-title":"Disturbances in peripheral blood B cell subpopulations in autoimmune patients.","volume":"11","author":"Potter","year":"2002","journal-title":"Lupus"},{"key":"R5-25-20210204","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/ar603","article-title":"Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjogrens syndrome.","volume":"4","author":"Dorner","year":"2002","journal-title":"Arthritis Res"},{"key":"R6-25-20210204","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"Suppl II","key":"R7-25-20210204","doi-asserted-by":"crossref","first-page":"ii55","DOI":"10.1136\/ard.62.suppl_2.ii55","article-title":"B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.","volume":"62","author":"Shaw","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R8-25-20210204","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"Suppl II","key":"R9-25-20210204","doi-asserted-by":"crossref","first-page":"ii55","DOI":"10.1136\/ard.62.suppl_2.ii55","article-title":"B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.","volume":"62","author":"Shaw","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R10-25-20210204","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary sjogrens syndrome.","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R11-25-20210204","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/art.11109","article-title":"Improvement in sjogrens syndrome following therapy with rituximab for marginal zone lymphoma.","volume":"49","author":"Somer","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R12-25-20210204","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis.","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R13-25-20210204","first-page":"149","article-title":"Prednisone and piroxicam for treatment of primary Sjogrens syndrome.","volume":"11","author":"Fox","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"R14-25-20210204","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard.2006.052647","article-title":"Progression of salivary gland dysfunction in patients with Sjogrens syndrome.","volume":"66","author":"Pijpe","year":"2007","journal-title":"Ann Rheum Dis"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0b013e318074e44d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:47:55Z","timestamp":1737323275000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-200708000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e318074e44d","relation":{},"ISSN":["0277-3740"],"issn-type":[{"type":"print","value":"0277-3740"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}